List of Excipients in Branded Drug TOPCARE MIGRAINE RELIEF

« Back to Dashboard

Generic Drugs Containing TOPCARE MIGRAINE RELIEF

Company	Ingredient	NDC	Excipient
Topco Associates LLC	acetaminophen, aspirin, caffeine	36800-533	CARNAUBA WAX
Topco Associates LLC	acetaminophen, aspirin, caffeine	36800-533	CELLULOSE, MICROCRYSTALLINE
Topco Associates LLC	acetaminophen, aspirin, caffeine	36800-533	CROSPOVIDONE
Topco Associates LLC	acetaminophen, aspirin, caffeine	36800-533	FD&C BLUE NO. 1 ALUMINUM LAKE
Topco Associates LLC	acetaminophen, aspirin, caffeine	36800-533	HYPROMELLOSE
Topco Associates LLC	acetaminophen, aspirin, caffeine	36800-533	POVIDONE
Topco Associates LLC	acetaminophen, aspirin, caffeine	36800-533	PROPYLENE GLYCOL

What are the Most Frequently-Used Excipients in TOPCARE MIGRAINE RELIEF?

# Of NDCs	Excipient
2	CARNAUBA WAX
2	CELLULOSE, MICROCRYSTALLINE
2	CROSPOVIDONE
1	D&C YELLOW NO. 10
1	FD&C BLUE NO. 1
1	FD&C BLUE NO. 1 ALUMINUM LAKE
1	FERROSOFERRIC OXIDE

TopCare Migraine Relief Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

TopCare Migraine Relief is an OTC combination analgesic generally marketed with acetaminophen 250 mg, aspirin 250 mg, and caffeine 65 mg per caplet. Its commercial position depends less on active-ingredient exclusivity than on low-cost manufacturing, tolerability, dosage-form differentiation, packaging, and retail-channel economics. The core combination has no meaningful composition-of-matter patent barrier, and FDA OTC monograph compliance is more relevant than Orange Book protection.

What is TopCare Migraine Relief?

TopCare Migraine Relief is a private-label oral analgesic positioned as an equivalent to branded acetaminophen-aspirin-caffeine migraine products, including Excedrin Migraine.

Attribute	Product profile
Dosage form	Oral caplet or tablet, depending on product version
Acetaminophen	250 mg per unit
Aspirin	250 mg per unit
Caffeine	65 mg per unit
Therapeutic category	OTC headache and migraine relief
Regulatory route	OTC monograph or private-label equivalent pathway
Likely commercial owner	TopCare retail/private-label platform
Patent exposure	Low for the active combination
Biosimilar exposure	None
Primary differentiation	Price, packaging, dosage form, excipient profile, and retail placement

The active combination is intended to provide analgesic, anti-inflammatory, and caffeine-enhanced headache relief. FDA labeling requirements for acetaminophen, aspirin, and caffeine drive most of the product’s regulatory risk. The excipients generally support manufacturability, tablet integrity, disintegration, coating, color, and stability rather than therapeutic exclusivity.

What excipients are likely used in TopCare Migraine Relief?

Public retail labeling identifies the active ingredients but may not consistently disclose the complete qualitative and quantitative excipient formula across every NDC or contract-manufactured version. A conventional immediate-release caplet is likely to use the following excipient functions.

Excipient function	Common candidate materials	Commercial purpose
Diluent	Microcrystalline cellulose, starch	Controls tablet weight and compressibility
Binder	Povidone, pregelatinized starch	Improves granule and tablet cohesion
Disintegrant	Croscarmellose sodium, sodium starch glycolate	Promotes rapid tablet breakup
Lubricant	Magnesium stearate	Reduces ejection force and tooling friction
Glidant	Colloidal silicon dioxide	Improves powder flow
Coating polymer	Hypromellose	Protects the core and improves swallowability
Opacifier	Titanium dioxide or equivalent	Provides opacity and appearance control
Colorant	FDA-permitted yellow or orange dyes	Supports product identification
Surfactant	Sodium lauryl sulfate or similar material	Improves wetting and coating performance
Anti-adherent	Talc	Reduces sticking during compression or coating

Which excipients matter most for migraine product performance?

The most commercially relevant excipient decisions concern disintegration, dissolution, tablet size, coating, and gastrointestinal tolerability.

A rapid-disintegration formulation can support consumer expectations for faster relief, but the product still must meet applicable dissolution and quality specifications. Excessive lubricant use, especially magnesium stearate, can slow wetting and dissolution. Excessive hydrophobic coating can create a similar problem.

The aspirin component creates a second design issue. Aspirin can hydrolyze to salicylic acid and acetic acid under unfavorable moisture conditions. Moisture-barrier packaging, controlled granulation, and appropriate coating selection can therefore have more value than adding complex excipients.

Caffeine can create taste and odor concerns if the tablet is chewed or partially dissolved. Film coating and an opaque blister package can improve consumer acceptability without changing the active formulation.

How should the excipient strategy be optimized?

Immediate-release caplet strategy

The lowest-risk commercial formulation is a conventional immediate-release caplet using established excipients with broad regulatory acceptance. The target profile should include:

• Rapid disintegration and dissolution.
• Low tablet weight and manageable caplet dimensions.
• Adequate mechanical strength during bottling and distribution.
• Low moisture uptake.
• Stable aspirin assay and impurity profile.
• Consistent content uniformity across all three active ingredients.
• Coating sufficient to improve swallowability without delaying release.

A direct-compression formulation could reduce manufacturing steps, but the three active ingredients have different particle characteristics, densities, and flow behavior. Segregation and content-uniformity risk must be controlled through particle-size engineering, preblending, granulation, or validated mixing controls.

Gastrointestinal-tolerability strategy

Aspirin and acetaminophen create an opportunity for a gentler product position, but excipients cannot eliminate the dose-related gastrointestinal and hepatic risks associated with the active ingredients.

Potential approaches include:

1. A film-coated caplet to reduce direct oral contact and improve swallowing.
2. A lower-irritancy excipient system with limited surfactant and controlled lubricant levels.
3. A smaller caplet achieved through higher-density excipients and optimized compression.
4. A blister package that limits moisture exposure and improves dose tracking.
5. A formulation that avoids unnecessary dyes, lactose, or other excipients relevant to specific consumer preferences.

An enteric-coated version would create a different product concept and could delay release. It would also require additional development work and may weaken the conventional migraine-relief positioning if consumers expect rapid action.

Caffeine-free formulation

A caffeine-free variant would target consumers who experience insomnia, palpitations, anxiety, or caffeine sensitivity. It would require a separate active-ingredient strength and labeling strategy rather than a simple excipient change.

The formulation could preserve the acetaminophen-aspirin combination while removing caffeine. That creates a potentially attractive line extension but reduces direct equivalence with established acetaminophen-aspirin-caffeine products. The commercial case would depend on whether the retailer wants a broader headache portfolio rather than a direct low-price substitute.

Dye-free and excipient-reduced formulation

A dye-free caplet could support clean-label positioning and reduce sensitivity concerns. Removing colorants may also simplify regulatory and supply-chain management. The tradeoff is weaker visual differentiation between product strengths and potentially less recognizable shelf appearance.

An excipient-reduced formulation could be marketed to consumers seeking a shorter inactive-ingredient list. The product would still require conventional binders, lubricants, disintegrants, and processing aids unless the manufacturing process is substantially redesigned.

What FDA regulatory status applies to TopCare Migraine Relief?

TopCare Migraine Relief is an OTC drug product, not a biologic. Its regulatory analysis is based on the FDA framework for internal analgesic, antipyretic, and antirheumatic products, including the applicable provisions of 21 C.F.R. part 343 and current FDA labeling requirements.

The combination of acetaminophen, aspirin, and caffeine is an established OTC product concept. A private-label manufacturer generally does not need to develop a novel clinical program if the product conforms to the applicable monograph conditions or is marketed under an appropriate FDA authorization.

Regulatory issue	Assessment
NDA exclusivity	No apparent product-specific exclusivity basis for the private-label product
OTC monograph	Central regulatory pathway
ANDA requirement	Depends on the exact marketed product and regulatory basis
New clinical efficacy program	Generally not expected for a compliant established combination
Labeling	Must satisfy acetaminophen, aspirin, caffeine, migraine, pregnancy, bleeding, and liver-safety requirements
NDC registration	Required for the marketed product and manufacturer
Postmarket controls	Complaint handling, adverse-event reporting, stability, quality, and recall readiness

FDA has imposed extensive acetaminophen labeling and safety requirements because of the risk of severe liver injury from overdose and unintentional combination use.[1] Aspirin labeling also requires attention to gastrointestinal bleeding, bleeding risk, pediatric viral illness warnings, and pregnancy-related restrictions.[2]

What patents protect TopCare Migraine Relief?

No meaningful composition-of-matter patent protection is expected for the acetaminophen-aspirin-caffeine combination. These active ingredients and the broad therapeutic concept are long-established.

IP category	Risk level	Analysis
Active-ingredient patents	Very low	Acetaminophen, aspirin, and caffeine are long-established molecules
Combination patent	Low	Broad combination protection is unlikely to remain enforceable
Immediate-release formulation patents	Low to moderate	Could exist for a specific branded product, but a conventional private-label caplet can often design around them
Method-of-use patents	Low	Migraine and headache uses are established
Packaging patents	Low	Child-resistant, unit-dose, or moisture-barrier designs may be protectable in narrow forms
Manufacturing patents	Low to moderate	Process claims may affect a particular supplier but rarely block the entire category
Trademark risk	Product-specific	Brand names, trade dress, and label presentation require clearance

Is TopCare Migraine Relief listed in the Orange Book?

TopCare Migraine Relief should not be assumed to have an Orange Book-listed NDA or patent estate. Orange Book relevance depends on the specific FDA application and NDC. A private-label OTC product marketed under monograph conditions may not present the same Orange Book patent-listing profile as an innovative prescription product.

The practical consequence is that a generic competitor would not normally face a conventional Paragraph IV challenge directed at TopCare’s retail brand. Paragraph IV litigation is associated primarily with abbreviated applications referencing an NDA containing listed patents. For a monograph-compliant OTC analgesic, the principal barriers are formulation execution, manufacturing scale, FDA compliance, retailer access, and brand economics.

When does TopCare Migraine Relief lose exclusivity?

TopCare Migraine Relief has no apparent product-specific patent exclusivity period comparable to a patented prescription drug. Its commercial protection comes from private-label contracting, retailer shelf allocation, supply agreements, packaging, and price positioning.

The active combination is open to competition from:

• Excedrin Migraine and other branded products.
• Store-brand acetaminophen-aspirin-caffeine products.
• Single-ingredient acetaminophen, aspirin, or ibuprofen.
• Caffeine-containing headache products.
• Liquid gels, tablets, caplets, powders, and orally disintegrating products.

A competitor can generally enter without waiting for patent expiration if it satisfies the applicable FDA requirements and avoids protected branding or proprietary formulation claims.

What commercial opportunities exist for excipient innovation?

1. Premium rapid-release caplet

A conventional caplet can be repositioned with validated rapid disintegration and dissolution. The commercial claim must remain within FDA-compliant labeling boundaries. The product could support a higher retail price than a basic store-brand tablet if the retailer accepts a differentiated SKU.

2. Unit-dose blister packaging

Blister packaging can improve portability, dose tracking, moisture protection, and pharmacy-counter presentation. It also creates an opportunity for travel packs and workplace first-aid placement.

The downside is higher packaging cost than a high-count bottle. The strategy is strongest for 2-, 4-, or 10-dose formats rather than large household packages.

3. Dye-free and simplified excipient product

A dye-free version can target consumers seeking fewer color additives. The product can be positioned as a cleaner-label alternative without changing the active ingredients.

4. Caffeine-free line extension

A caffeine-free acetaminophen-aspirin product can address a different consumer segment. The main commercial risk is confusion between the caffeine-containing and caffeine-free versions, especially if packaging uses similar colors.

5. Liquid-gel or softgel format

A softgel can improve swallowability and provide a premium alternative to a caplet. It requires compatibility work involving gelatin or vegetarian shell materials, fill uniformity, oxygen and moisture control, and aspirin stability.

The format may increase manufacturing cost and create a more complex supply chain. It is better suited to a national-brand or premium private-label strategy than to the lowest-price channel.

6. Orally disintegrating or chewable product

A chewable format could appeal to consumers who have difficulty swallowing tablets. Caffeine and aspirin create taste challenges, so flavor masking, sweeteners, and coating systems would be important. The product would also need careful child-safety positioning because accidental ingestion of acetaminophen or aspirin can create serious risks.

How does TopCare compare with Excedrin Migraine?

Factor	TopCare Migraine Relief	Excedrin Migraine
Active combination	Generally acetaminophen, aspirin, and caffeine	Acetaminophen, aspirin, and caffeine
Primary advantage	Lower retail price	Brand recognition and consumer familiarity
Patent moat	Limited	Limited for the basic combination
Key differentiation	Retailer brand and value	Marketing, packaging, and brand equity
Excipient opportunity	Cost-efficient reformulation and line extensions	Premium delivery formats and branded innovation
Competitive threat	Other private labels and store brands	Private labels and alternative analgesics
Main regulatory risk	Labeling, quality, monograph compliance	Labeling, quality, and brand-wide manufacturing controls

The products are likely to compete primarily on price, availability, package size, and consumer trust rather than on fundamental pharmacology.

What generic entry risks exist for TopCare Migraine Relief?

Generic and private-label entry risk is high because the active ingredients are widely available and the formulation category is mature. A new entrant could compete through:

• Lower-cost direct compression.
• Contract manufacturing in high-volume facilities.
• Multi-count bottles.
• Unit-dose blister packs.
• Dye-free or caffeine-free variants.
• Retailer-exclusive packaging.
• E-commerce multipacks.
• Subscription and replenishment programs.

The strongest barriers are commercial rather than legal. A new supplier must secure retail distribution, meet retailer quality audits, maintain supply continuity, and avoid recalls involving acetaminophen potency, aspirin degradation, labeling errors, or foreign particulate contamination.

What manufacturing and IP barriers affect the product?

Manufacturing barriers are manageable but not trivial. The principal technical risks are:

• Segregation of the three active ingredients during blending.
• Aspirin degradation under elevated humidity.
• Acetaminophen content uniformity and compression behavior.
• Capping, sticking, or lamination during tableting.
• Delayed dissolution from excessive lubrication or coating.
• Color and coating variability across high-volume batches.
• Packaging failure that permits moisture ingress.
• Supplier concentration for specialized coating or softgel components.

IP barriers may arise from narrow formulation or delivery-system patents held by a branded competitor. A conventional uncoated or film-coated caplet using established excipients is less likely to encounter a blocking patent than a specialized extended-release, liquid-gel, or orally disintegrating formulation.

How strong is the commercial patent estate for TopCare Migraine Relief?

The estate is weak as a patent-based franchise and stronger as a retail execution platform. The product has limited legal exclusivity but can remain commercially durable through:

• Retailer control of shelf placement.
• Low-cost sourcing.
• High consumer familiarity with the active combination.
• Efficient packaging and distribution.
• Contract manufacturing capacity.
• Private-label pricing.
• Incremental dosage-form and excipient innovation.

A patent strategy would have the greatest value in a differentiated formulation, moisture-control package, softgel system, orally disintegrating dosage form, or validated rapid-release platform. Broad claims covering the three active ingredients alone would face substantial validity and prior-art risk.

Key Takeaways

• TopCare Migraine Relief is generally an acetaminophen-aspirin-caffeine OTC combination.
• The product has little apparent patent-based exclusivity.
• Orange Book and Paragraph IV exposure is likely limited compared with prescription NDA products.
• Excipient value lies in disintegration, dissolution, stability, swallowability, taste masking, and manufacturing efficiency.
• Aspirin moisture stability and three-ingredient content uniformity are central technical concerns.
• The most credible commercial extensions are dye-free, caffeine-free, rapid-release, blister-pack, liquid-gel, and orally disintegrating formats.
• Generic entry risk is high, while manufacturing, quality, retail access, and supply continuity are the practical barriers.
• A patentable opportunity would require a specific differentiated formulation, delivery system, packaging architecture, or manufacturing process.

FAQs

Is TopCare Migraine Relief the same as Excedrin Migraine?

It is generally positioned as a store-brand equivalent using the same core active combination, but inactive ingredients, manufacturing site, packaging, and FDA product registration can differ.

Can TopCare Migraine Relief be reformulated without caffeine?

Yes. A caffeine-free version would be a separate formulation and labeling configuration, not a simple excipient modification.

Does aspirin stability require special packaging?

Aspirin is sensitive to moisture-related degradation. A suitable bottle closure, desiccant strategy, blister package, and validated stability program can reduce that risk.

Can a company patent a new TopCare Migraine Relief excipient system?

Potentially, but protection would need to focus on a novel and non-obvious formulation, dosage form, stability result, delivery system, or manufacturing process. The basic active combination is unlikely to support broad new patent claims.

Is a liquid-gel version commercially attractive?

It can support premium positioning and improved swallowability, but higher manufacturing and packaging costs make it less suitable for the lowest-price private-label segment.

References

1. U.S. Food and Drug Administration. (n.d.). Acetaminophen and liver injury: Q&A for consumers. https://www.fda.gov
2. U.S. Food and Drug Administration. (n.d.). OTC monograph M013: Internal analgesic, antipyretic, and antirheumatic drug products. https://www.accessdata.fda.gov
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services. https://www.fda.gov
4. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov
5. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic products for over-the-counter human use. https://www.ecfr.gov